CL
COLGATE PALMOLIVE CO
$90.66
+0.09%
$72.5B
No data for this timeframe.
Vol
Market Cap$72.5B
Cap SizeLarge Cap
Analyst ConsensusBuy (67%)
Inst. Holders50 funds
Inst. Value$34.3B
Inst. Activity35 buys / 15 sells
Insider Activity0B / 10S
Insider Net $-$26.0M
Reddit Sentiment50° Neutral
SEC Reports3
Exchange NYSE·Sector Perfumes, Cosmetics & Other Toilet Preparations·Inc. DE·CIK 0000021665·Prev Close $90.58
Recent Activity
Jun 13, 2026
clinical_trial_readout
Results Pending: Colgate 360 SupraClean Manual Toothbrush brush with 0.76% Na MFP, (1000 ppm F) (Phase 3) — Completed 7d ago
Trial: Bacterial Reduction for a Manual Toothbrush With a 360-Degree Mouth Cleaner Design Versus a S
May 16, 2026
SEC
A federal district court denied Colgate-Palmolive's motion to dismiss two putative class actions (the 'Mouthrinse Action
COURT-RULING — Impact 6/10
May 15, 2026
Insider
Malcolm Gregory sold 2,300 shares
EVP and Controller @ $88.44 ($203.4K)
May 11, 2026
Insider
BILBREY JOHN P was granted 2,075 shares
Director
May 11, 2026
Insider
BILBREY JOHN P was granted 2,424 shares
Director
Apr 9, 2026
SEC
Colgate-Palmolive announced the retirement of Chief Legal Officer Jennifer M. Daniels and the appointment of Betsy Fishb
8-K — Impact 3/10
Mar 25, 2026
SEC
Colgate-Palmolive filed a definitive proxy statement for its 2026 Annual Meeting, seeking shareholder approval for the e
DEFA14A — Impact 3/10
Inst.
DIAMOND HILL CAPITAL MANAGEMENT — TRIM
5,406,578 shares ($460.8M)
Price Targets
$95.85
+5.7% upside
Buy
Current $90.66
Low $80.00
Median $98.00
High $105.00
20 analysts
$80.00
$105.00
Analyst Ratings
5Strong Buy
15Buy
9Hold
0Sell
1Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 11, 2026 | Bernstein | INITIATE | Market Perform |
| May 5, 2026 | Barclays | MAINTAIN | Equal-Weight → Equal-Weight |
| May 4, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
| May 4, 2026 | UBS | MAINTAIN | Buy → Buy |
| May 4, 2026 | RBC Capital | REITERATE | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.95 | $0.92 — $0.98 | 3% YoY | 17 |
| Next Q | $0.92 | $0.90 — $0.96 | 1% YoY | 17 |
| Current FY | $3.81 | $3.75 — $3.94 | 3% YoY | 20 |
| Next FY | $4.04 | $3.93 — $4.24 | 6% YoY | 20 |
Latest Reports
BEARISH
COURT-RULING
6/10
A federal district court denied Colgate-Palmolive's motion to dismiss two putative class actions (the 'Mouthrinse Action
May 16, 2026
NEUTRAL
8-K
3/10
Colgate-Palmolive announced the retirement of Chief Legal Officer Jennifer M. Daniels and the appointment of Betsy Fishb
Apr 9, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $6.2B | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $4.5B | — |
| STATE STREET CORP | $4.1B | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2.0B | — |
| MORGAN STANLEY | $1.8B | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 15, 2026 | Malcolm Gregory | SELL | $203.4K |
| May 11, 2026 | BILBREY JOHN | A | $0.00 |
| May 11, 2026 | BILBREY JOHN | A | $0.00 |
| May 11, 2026 | BOERNER CHRISTOPHER | A | $0.00 |
| May 11, 2026 | BOERNER CHRISTOPHER | A | $0.00 |
Reddit Sentiment
50°▼
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $34.3B total value (401,994,330 shares) as of 2026-Q1. Top holders: BlackRock,, VANGUARD, STATE. Net buying activity: 35 institutions added/increased vs 15 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 72,643,002 | $6.2B | 18.1% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 52,219,824 | $4.5B | 13.0% | — |
| 3 | STATE STREET CORP | 47,719,482 | $4.1B | 11.9% | — |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 23,822,746 | $2.0B | 5.9% | — |
| 5 | MORGAN STANLEY | 20,881,354 | $1.8B | 5.2% | — |
| 6 | DEUTSCHE BANK AG\ | 11,928,161 | $1.0B | 3.0% | — |
| 7 | GOLDMAN SACHS GROUP INC | 9,475,834 | $807.6M | 2.4% | — |
| 8 | FMR LLC | 9,008,985 | $767.8M | 2.2% | — |
| 9 | Invesco Ltd. | 8,338,993 | $710.7M | 2.1% | — |
| 10 | First Eagle Investment Management, LLC | 8,116,782 | $691.8M | 2.0% | — |
| 11 | BANK OF AMERICA CORP /DE/ | 6,637,597 | $565.7M | 1.7% | — |
| 12 | FRANKLIN RESOURCES INC | 5,879,731 | $501.1M | 1.5% | — |
| 13 | Legal & General Group Plc | 5,716,974 | $487.3M | 1.4% | — |
| 14 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 5,584,998 | $476.0M | 1.4% | — |
| 15 | DIAMOND HILL CAPITAL MANAGEMENT INC | 5,406,578 | $460.8M | 1.3% | TRIM -25.3% |
| 16 | WELLINGTON MANAGEMENT GROUP LLP | 5,357,752 | $456.6M | 1.3% | TRIM -29.0% |
| 17 | AMERIPRISE FINANCIAL INC | 5,200,321 | $443.3M | 1.3% | ADD +70.7% |
| 18 | DIMENSIONAL FUND ADVISORS LP | 5,190,038 | $442.3M | 1.3% | — |
| 19 | Amundi | 5,184,339 | $441.9M | 1.3% | — |
| 20 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 5,121,302 | $436.5M | 1.3% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| DIAMOND HILL CAPITAL MANAGEMENT INC | TRIM | 7,233,374 | 5,406,578 | -25.3% | $460.8M | 2026-Q1 |
| WELLINGTON MANAGEMENT GROUP LLP | TRIM | 7,542,612 | 5,357,752 | -29.0% | $456.6M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | ADD | 3,047,173 | 5,200,321 | +70.7% | $443.3M | 2026-Q1 |
| Alyeska Investment Group, L.P. | ADD | 1,673,802 | 2,217,425 | +32.5% | $189.0M | 2026-Q1 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | DOUBLED | 31,865 | 1,927,630 | +5949.4% | $164.3M | 2026-Q1 |
| CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | TRIM | 3,109,934 | 1,898,485 | -39.0% | $161.8M | 2026-Q1 |
| AustralianSuper Pty Ltd | ADD | 1,090,888 | 1,494,272 | +37.0% | $127.4M | 2026-Q1 |
| Russell Investments Group, Ltd. | ADD | 956,855 | 1,457,319 | +52.3% | $124.4M | 2026-Q1 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | DOUBLED | 444,922 | 1,424,751 | +220.2% | $121.4M | 2026-Q1 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | ADD | 1,025,474 | 1,407,406 | +37.2% | $120.0M | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 889,402 | 1,241,878 | +39.6% | $105.8M | 2026-Q1 |
| Ninety One UK Ltd | ADD | 764,928 | 1,209,402 | +58.1% | $103.1M | 2026-Q1 |
| NORDEA INVESTMENT MANAGEMENT AB | TRIM | 4,667,298 | 1,171,760 | -74.9% | $97.9M | 2026-Q1 |
| ENVESTNET ASSET MANAGEMENT INC | ADD | 614,899 | 1,131,477 | +84.0% | $96.4M | 2026-Q1 |
| Allianz Asset Management GmbH | ADD | 560,018 | 855,611 | +52.8% | $72.9M | 2026-Q1 |
| AMF Tjanstepension AB | TRIM | 1,568,041 | 850,709 | -45.7% | $72.5M | 2026-Q1 |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | ADD | 471,788 | 763,624 | +61.9% | $65.1M | 2026-Q1 |
| CAPITOLIS LIQUID GLOBAL MARKETS LLC | TRIM | 980,627 | 678,000 | -30.9% | $57.8M | 2026-Q1 |
| Woodline Partners LP | TRIM | 895,510 | 620,428 | -30.7% | $52.9M | 2026-Q1 |
| FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | ADD | 345,724 | 561,024 | +62.3% | $47.8M | 2026-Q1 |
| Clearbridge Investments, LLC | ADD | 385,024 | 559,401 | +45.3% | $47.7M | 2026-Q1 |
| Korea Investment CORP | TRIM | 762,373 | 481,910 | -36.8% | $41.1M | 2026-Q1 |
| FIFTH THIRD BANCORP | DOUBLED | 82,990 | 474,692 | +472.0% | $40.5M | 2026-Q1 |
| EXCHANGE TRADED CONCEPTS, LLC | DOUBLED | 139,134 | 472,650 | +239.7% | $40.3M | 2026-Q1 |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | DOUBLED | 50,079 | 429,122 | +756.9% | $36.6M | 2026-Q1 |
16 unique insiders with 45 transactions. Net insider value: -$26.0M ($0.00 bought, $26.0M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 15, 2026 | Malcolm Gregory | EVP and Controller | SELL | 2,300 | $88.44 | $203.4K |
| May 11, 2026 | BILBREY JOHN P | Director | AWARD | 2,075 | — | — |
| May 11, 2026 | BILBREY JOHN P | Director | AWARD | 2,424 | — | — |
| May 11, 2026 | BOERNER CHRISTOPHER S. | Director | AWARD | 1,383 | — | — |
| May 11, 2026 | BOERNER CHRISTOPHER S. | Director | AWARD | 2,020 | — | — |
| May 11, 2026 | Nelson Kimberly A | Director | AWARD | 2,075 | — | — |
| May 11, 2026 | CAHILL JOHN T | Director | AWARD | 2,075 | — | — |
| May 11, 2026 | Nelson Kimberly A | Director | AWARD | 2,424 | — | — |
| May 11, 2026 | Newman Brian | Director | AWARD | 2,075 | — | — |
| May 11, 2026 | Newman Brian | Director | AWARD | 2,424 | — | — |
| May 11, 2026 | HUNDMEJEAN MARTINA | Director | AWARD | 2,075 | — | — |
| May 11, 2026 | HUNDMEJEAN MARTINA | Director | AWARD | 2,424 | — | — |
| May 11, 2026 | HARRIS C MARTIN | Director | AWARD | 1,556 | — | — |
| May 11, 2026 | HARRIS C MARTIN | Director | AWARD | 2,424 | — | — |
| May 11, 2026 | NORRINGTON LORRIE M | Director | AWARD | 2,075 | — | — |
| May 11, 2026 | NORRINGTON LORRIE M | Director | AWARD | 2,424 | — | — |
| May 11, 2026 | Edwards Lisa | Director | AWARD | 2,075 | — | — |
| May 11, 2026 | Edwards Lisa | Director | AWARD | 2,424 | — | — |
| May 11, 2026 | CAHILL JOHN T | Director | AWARD | 2,424 | — | — |
| May 7, 2026 | Massey Sally | Chief People Officer | SELL | 8,599 | $87.41 | $751.6K |
| Apr 1, 2026 | NORRINGTON LORRIE M | Director | AWARD | 294 | $89.05 | $26.2K |
| Apr 1, 2026 | Newman Brian | Director | AWARD | 210 | $89.05 | $18.7K |
| Apr 1, 2026 | BILBREY JOHN P | Director | AWARD | 266 | $89.05 | $23.7K |
| Feb 23, 2026 | Wallace Noel R. | Chairman, President & CEO | AWARD | 136,710 | — | — |
| Feb 23, 2026 | Daniels Jennifer | CLO and Secretary | AWARD | 25,742 | — | — |
| Feb 23, 2026 | Massey Sally | Chief Human Resources Officer | AWARD | 16,805 | — | — |
| Feb 23, 2026 | Tsourapas Panagiotis | COO, Eur., APac, Afr Eur, Skin | AWARD | 25,742 | — | — |
| Feb 23, 2026 | Hazlin John | Chief Growth Officer | AWARD | 12,803 | — | — |
| Feb 23, 2026 | Malcolm Gregory | EVP and Controller | AWARD | 6,268 | — | — |
| Feb 23, 2026 | SUTULA STANLEY J III | Chief Financial Officer | AWARD | 38,678 | — | — |
| Feb 12, 2026 | Tsourapas Panagiotis | COO, Eur., APac, Afr Eur, Skin | EXERCISE | 15,000 | $76.41 | $1.1M |
| Feb 12, 2026 | Tsourapas Panagiotis | COO, Eur., APac, Afr Eur, Skin | SELL | 15,000 | $97.81 | $1.5M |
| Feb 11, 2026 | Tsourapas Panagiotis | COO, Eur., APac, Afr Eur, Skin | EXERCISE | 35,000 | $76.41 | $2.7M |
| Feb 11, 2026 | Tsourapas Panagiotis | COO, Eur., APac, Afr Eur, Skin | SELL | 35,000 | $94.61 | $3.3M |
| Feb 10, 2026 | Hazlin John | Chief Growth Officer | EXERCISE | 20,989 | $76.41 | $1.6M |
| Feb 10, 2026 | Hazlin John | Chief Growth Officer | SELL | 20,989 | $94.25 | $2.0M |
| Feb 6, 2026 | Malcolm Gregory | EVP and Controller | EXERCISE | 12,747 | $76.41 | $974.0K |
| Feb 6, 2026 | Malcolm Gregory | EVP and Controller | SELL | 12,747 | $94.91 | $1.2M |
| Feb 5, 2026 | Massey Sally | Chief Human Resources Officer | EXERCISE | 15,851 | $76.41 | $1.2M |
| Feb 5, 2026 | Massey Sally | Chief Human Resources Officer | SELL | 15,851 | $95.03 | $1.5M |
| Feb 4, 2026 | Wallace Noel R. | Chairman, President & CEO | SELL | 45,568 | $93.91 | $4.3M |
| Feb 4, 2026 | SUTULA STANLEY J III | Chief Financial Officer | EXERCISE | 97,843 | $81.78 | $8.0M |
| Feb 4, 2026 | SUTULA STANLEY J III | Chief Financial Officer | SELL | 97,843 | $94.27 | $9.2M |
| Feb 4, 2026 | Daniels Jennifer | CLO and Secretary | EXERCISE | 22,000 | $72.29 | $1.6M |
| Feb 4, 2026 | Daniels Jennifer | CLO and Secretary | SELL | 22,000 | $94.34 | $2.1M |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 2 neutral. Avg impact: 4.0/10.
BEARISH
COURT-RULING
6/10
A federal district court denied Colgate-Palmolive's motion to dismiss two putative class actions (th
May 16, 2026
NEUTRAL
8-K
3/10
Colgate-Palmolive announced the retirement of Chief Legal Officer Jennifer M. Daniels and the appoin
Apr 9, 2026
NEUTRAL
DEFA14A
3/10
Colgate-Palmolive filed a definitive proxy statement for its 2026 Annual Meeting, seeking shareholde
Mar 25, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (67% buy). Based on 30 analysts: 5 strong buy, 15 buy, 9 hold, 0 sell, 1 strong sell.
Analyst Price Targets
$95.85 mean target
+5.7% upside
Buy (2.05)
$80.00 Low
$105.00 High
| Metric | Value |
|---|---|
| Current Price | $90.66 |
| Target Low | $80.00 |
| Target Mean | $95.85 |
| Target Median | $98.00 |
| Target High | $105.00 |
| # Analysts | 20 |
| Recommendation | Buy (2.05) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.95 | $0.92 | $0.98 | 3.1% | -0.0% | 1↑ 14↓ | $5.4B | 4.9% | 17 |
| Next Q 2026-09-30 |
$0.92 | $0.90 | $0.96 | 1.3% | +0.1% | 0↑ 14↓ | $5.4B | 4.5% | 17 |
| Current FY 2026-12-31 |
$3.81 | $3.75 | $3.94 | 3.3% | +0.0% | 2↑ 12↓ | $21.4B | 5.2% | 20 |
| Next FY 2027-12-31 |
$4.04 | $3.93 | $4.24 | 6.0% | +0.0% | 2↑ 12↓ | $22.2B | 3.3% | 20 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.948 | |
| 7d ago | $0.949 | -0.000 |
| 30d ago | $0.949 | -0.000 |
| 60d ago | $0.963 | -0.015 |
| 90d ago | $0.968 | -0.020 |
15 analyst firms have rated this stock: 4 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 11, 2026 | Bernstein | INITIATE | — | Market Perform |
| May 5, 2026 | Barclays | MAINTAIN | Equal-Weight | Equal-Weight |
| May 4, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| May 4, 2026 | UBS | MAINTAIN | Buy | Buy |
| May 4, 2026 | RBC Capital | REITERATE | Outperform | Outperform |
| Apr 23, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Apr 21, 2026 | Rothschild & Co | UPGRADE | Neutral | Buy |
| Apr 17, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Apr 14, 2026 | Barclays | MAINTAIN | Equal-Weight | Equal-Weight |
| Apr 10, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Apr 8, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Apr 8, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Apr 7, 2026 | UBS | MAINTAIN | Buy | Buy |
| Mar 30, 2026 | Deutsche Bank | UPGRADE | Hold | Buy |
| Feb 3, 2026 | Barclays | MAINTAIN | Equal-Weight | Equal-Weight |
| Feb 2, 2026 | Jefferies | MAINTAIN | Hold | Hold |
| Feb 2, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Feb 2, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Feb 2, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Feb 2, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Feb 2, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Feb 2, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Feb 2, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Feb 2, 2026 | Deutsche Bank | MAINTAIN | Hold | Hold |
| Jan 16, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Jan 14, 2026 | UBS | MAINTAIN | Buy | Buy |
| Jan 13, 2026 | Wells Fargo | UPGRADE | Underweight | Equal-Weight |
| Jan 8, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| Jan 7, 2026 | Piper Sandler | UPGRADE | Neutral | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 15 | 9 | 0 | 1 | 67% | |
| May 1, 2026 | 5 | 15 | 9 | 0 | 1 | 67% | |
| Apr 1, 2026 | 5 | 14 | 10 | 0 | 1 | 63% | |
| Mar 1, 2026 | 5 | 14 | 10 | 0 | 1 | 63% | |
| Feb 1, 2026 | 5 | 14 | 10 | 0 | 1 | 63% | |
| Jan 1, 2026 | 5 | 13 | 10 | 1 | 1 | 60% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
31 mentions
8 bullish
8 bearish
27 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 9, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Jun 9, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Jun 2, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Jun 2, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 31, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| May 31, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| May 17, 2026 | 2 | 56° Neutral | 0 | 0 | 2 |
| May 17, 2026 | 2 | 56° Neutral | 0 | 0 | 2 |
| May 13, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| May 13, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Apr 29, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 29, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 16, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 16, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 6, 2026 | 2 | 67° Warm | 2 | 0 | 2 |
| Apr 6, 2026 | 2 | 67° Warm | 2 | 0 | 2 |
| Mar 31, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 31, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 18, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 18, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 11, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Mar 11, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Mar 1, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 1, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Feb 28, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
April 6: VIX 25 & ES 6645
▲ 1
💬 0
⚡ 0.5
April 6: VIX 25 & ES 6645
▲ 1
💬 0
⚡ 0.5
Jun 13, 2026
Clinical Trial
Bacterial Reduction for a Manual Toothbrush With a 360-Degree Mouth Cleaner Design Versus a Standard Toothbrush
Phase Phase 3 — COMPLETED
Jun 13, 2026
clinical_trial_readout
Results Pending: Colgate 360 SupraClean Manual Toothbrush brush with 0.76% Na MFP, (1000 ppm F) (Phase 3) — Completed 7d ago
Trial: Bacterial Reduction for a Manual Toothbrush With a 360-Degree Mouth Cleaner Design Versus a Standard Toothbrush
Sponsor: Colgate Palmolive
Phas
Jun 11, 2026
short_volume
Short Volume: CL — 59.1% short (0.8M / 1.4M)
Short: 836,143 | Exempt: 899 | TRF Vol: 1,414,208 | Short Ratio: 59.1% | Off-exchange volume (dark pool + OTC)
Jun 9, 2026
short_volume
Short Volume: CL — 57.4% short (1.1M / 1.9M)
Short: 1,109,556 | Exempt: 4,656 | TRF Vol: 1,934,371 | Short Ratio: 57.4% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: CL — 59.7% short (1.2M / 2.1M)
Short: 1,237,591 | Exempt: 723 | TRF Vol: 2,072,997 | Short Ratio: 59.7% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
short_volume
Short Volume: CL — 63.8% short (1.6M / 2.5M)
Short: 1,575,251 | Exempt: 235 | TRF Vol: 2,469,316 | Short Ratio: 63.8% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: CL — 57.3% short (0.7M / 1.3M)
Short: 723,513 | Exempt: 0 | TRF Vol: 1,262,556 | Short Ratio: 57.3% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: CL — 64.0% short (0.8M / 1.3M)
Short: 834,124 | Exempt: 113 | TRF Vol: 1,303,255 | Short Ratio: 64.0% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: CL — 65.0% short (0.9M / 1.4M)
Short: 899,718 | Exempt: 4,992 | TRF Vol: 1,385,036 | Short Ratio: 65.0% | Off-exchange volume (dark pool + OTC)
May 27, 2026
short_volume
Short Volume: CL — 58.6% short (0.7M / 1.2M)
Short: 709,727 | Exempt: 1,720 | TRF Vol: 1,210,452 | Short Ratio: 58.6% | Off-exchange volume (dark pool + OTC)
May 25, 2026
dark_pool
Dark Pool: CL — 4.7M shares, 85,968 trades
Week starting 2026-05-25. Total ATS volume: 4,743,061 shares across 85,968 trades.
May 21, 2026
short_volume
Short Volume: CL — 57.9% short (1.0M / 1.8M)
Short: 1,028,513 | Exempt: 2,816 | TRF Vol: 1,775,680 | Short Ratio: 57.9% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: CL — 62.9% short (1.3M / 2.1M)
Short: 1,316,156 | Exempt: 0 | TRF Vol: 2,092,067 | Short Ratio: 62.9% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: CL — 59.3% short (1.1M / 1.8M)
Short: 1,053,827 | Exempt: 2,239 | TRF Vol: 1,776,141 | Short Ratio: 59.3% | Off-exchange volume (dark pool + OTC)
May 18, 2026
dark_pool
Dark Pool: CL — 6.5M shares, 112,462 trades
Week starting 2026-05-18. Total ATS volume: 6,538,537 shares across 112,462 trades.
May 14, 2026
short_volume
Short Volume: CL — 64.7% short (1.5M / 2.2M)
Short: 1,454,300 | Exempt: 726 | TRF Vol: 2,247,835 | Short Ratio: 64.7% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
Clinical Trial
The Efficacy of a Battery Toothbrush in the Reduction of Established Plaque and Gingivitis
Phase Phase 3 — COMPLETED
Mar 30, 2026
Clinical Trial
Clinical Investigation to Assess the Efficacy of Manual Toothbrushes in the Reduction of Plaque and Gingivitis.
Phase Phase 2 — COMPLETED
Mar 30, 2026
Clinical Trial
Clinical Research Study to Assess the Efficacy of Two Brushing Regimens in the Reduction of Established Dental Plaque and Gingivitis.
Phase Phase 3 — COMPLETED
Mar 30, 2026
Clinical Trial
Efficacy of Manual Toothbrushes in Removing Tooth Stains
Phase Phase 3 — COMPLETED
Mar 27, 2026
Enforcement
Jason Harden, et al. v. Colgate-Palmolive Company; Tanisier Clayborne, et al. v. Colgate-Palmolive Company, et al.
Court ruling from District Court, N.D. Illinois. Docket: 1:25-cv-00362